IUPAC/Chemical Name
ethyl 2-(4-(4-chlorobenzyl)phenoxy)-2-methylbutanoate
InChi Key
YWQGBCXVCXMSLJ-UHFFFAOYSA-N
InChi Code
1S/C20H23ClO3/c1-4-20(3,19(22)23-5-2)24-18-12-8-16(9-13-18)14-15-6-10-17(21)11-7-15/h6-13H,4-5,14H2,1-3H3
SMILES Code
CCOC(=O)C(C)(CC)OC1=CC=C(CC2=CC=C(Cl)C=C2)C=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
346.85
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wanner C, Wieland H, Schollmeyer P, Hörl WH. Beclobrate:pharmacodynamic properties and therapeutic use in hyperlipidemia. Eur J Clin Pharmacol. 1991;40 Suppl 1:S85-9. PMID: 2044651.
2: Aebi U, Reinhart WH. Beclobrate and liver disease. Ann Intern Med. 1990 Sep 15;113(6):483. doi: 10.7326/0003-4819-113-6-483_2. PMID: 2386344.
3: Vouillamoz D, Schaller MD, Bianchi L, Chaubert P, Reinhart W, Armstrong D, Thorens J, Blum AL. Beclobrate and fatal acute hepatitis. Lancet. 1991 Aug 31;338(8766):581. doi: 10.1016/0140-6736(91)91155-n. PMID: 1678843.
4: Wanner C, Wieland H, Nauck M, Schaeffer G, Schollmeyer P, Hörl WH. Effective hypolipidaemic therapy with beclobrate in haemodialysis patients: interference with L-carnitine. Nephrol Dial Transplant. 1990;5(8):588-93. doi: 10.1093/ndt/5.8.588. PMID: 23275992.
5: Kritchevsky D, Klurfeld DM. Influence of beclobrate on gallstone formation in hamsters. Arzneimittelforschung. 1983;33(10):1471-2. PMID: 6686046.
6: Adrian RW, Ismail S, Jahn U. Pharmacological studies with beclobrate, a new hypolipidemic agent. Arzneimittelforschung. 1983;33(10):1464-8. PMID: 6686044.
7: Manzoni C, Lovati MR, Bonelli A, Galli G, Sirtori CR. Differential effects of beclobrate on lipid/lipoprotein distribution in normal and hypercholesterolemic rats. Eur J Pharmacol. 1990 Nov 6;190(1-2):39-49. doi: 10.1016/0014-2999(90)94110-j. PMID: 2076759.
8: Thiele K, Ahmed Q, Jahn U, Adrian RW. Neue Cholesterin- und Triglyceridspiegel-senkende Dephenylmethan-Derivate, Beclobrat und Eniclobrat- hydrochlorid. 1. Mitteilung: Synthese und Betrachtungen über die Zusammenhänge zwischen Aktivität und Struktur [Beclobrate and eniclobrate hydrochloride, new diphenylmethane derivatives as agents for lowering cholesterol and triglyceride levels. Part I: Synthesis and consideration of structure-activity relationships (author's transl)]. Arzneimittelforschung. 1979;29(5):711-20. German. PMID: 582967.
9: Avogaro P, Bittolo Bon G, Cazzolato G, Soldan S, Bufalino L. A cross-over controlled study on beclobrate versus bezafibrate in the treatment of type IIb hyperlipoproteinaemia. Drugs Exp Clin Res. 1989;15(6-7):325-33. PMID: 2686956.
10: Mayer S, Mutschler E, Spahn-Langguth H. Pharmacokinetic studies with the lipid-regulating agent beclobrate: enantiospecific assay for beclobric acid using a new fluorescent chiral coupling component (S-FLOPA). Chirality. 1991;3(1):35-42. doi: 10.1002/chir.530030108. PMID: 2039683.
